IVERIC bio has been granted a patent for nucleic acid therapeutics to treat complement-related disorders. The compound includes specific nucleotide sequences and binds to complement system protein C5. GlobalData’s report on IVERIC bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights IVERIC bio Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on IVERIC bio, Peptide pharmacophores was a key innovation area identified from patents. IVERIC bio's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Nucleic acid therapeutic for complement-related disorders

Source: United States Patent and Trademark Office (USPTO). Credit: IVERIC bio Inc

A recently granted patent (Publication Number: US11913000B2) discloses a compound or salt thereof with a specific sequence that binds to complement system protein C5. The compound includes 2'-fluoro nucleotides (fC and fU), 2'-OMe nucleotides (mG and mA), and an inverted deoxy thymidine (3T). Additionally, the compound contains 1,3-bis(mPEG)-propyl-2-(4-butamide), with the mPEG having a molecular weight greater than 10 kDA. This innovative compound is intended for use in pharmaceutical compositions for treating C5 complement protein, C5a, and/or C5b-9-mediated disorders.

Furthermore, the patent claims cover methods for treating various disorders such as myocardial injury related to cardiac surgeries and procedures, complement-mediated ocular tissue damage, and transplant rejection. The disclosed methods involve administering the compound or its pharmaceutically acceptable salt to patients in need of treatment. The pharmaceutical compositions include the compound along with a suitable carrier or vehicle to ensure effective delivery and therapeutic outcomes. Overall, the patent provides a novel approach to targeting C5 complement proteins and associated disorders, offering potential benefits in the treatment of a range of medical conditions related to the complement system.

To know more about GlobalData’s detailed insights on IVERIC bio, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies